secwatch.observer — SEC 8-K summary
======================================

Issuer:     Minerva Neurosciences, Inc. (NERV)
CIK:        0001598646
Form:       8-K
Filed at:   2024-02-27T23:59:59+00:00
Accession:  0001193125-24-047110
Event type: regulatory
Sentiment:  negative
Materiality: 1.00
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

FDA issues Complete Response Letter for roluperidone; NDA not approved
----------------------------------------------------------------------

- FDA cited single positive study insufficient; requires at least one additional positive well-controlled trial.
- CRL also demands data on co-administration with antipsychotics and clinically meaningful change.
- Safety database inadequate: too few subjects on 64 mg for 12+ months.
- Minerva will request a meeting with FDA to discuss path forward; CEO expresses disappointment.
- Roluperidone was targeting negative symptoms of schizophrenia, an unmet need.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1598646/000119312524047110/0001193125-24-047110-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1598646/000119312524047110/d795805d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-047110

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer